Company news

Erasca, Inc. news in 2024

Erasca, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Erasca Reports Third Quarter 2024 Business Updates and Financial Results

November 11, 2024

Erasca to Present at Upcoming Investor Conferences

November 4, 2024

Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise

October 23, 2024

Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib Plus Trametinib in RAS Q61X Mutant Solid Tumors as Oral Presentation at 36th EORTC-NCI-AACR Symposium

September 24, 2024

Erasca to Present at Upcoming Investor Conferences in September

August 28, 2024

Erasca Reports Second Quarter 2024 Business Updates and Financial Results

August 11, 2024

Erasca Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib in Patients with NRAS-Mutant Melanoma

June 17, 2024

Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

May 20, 2024

Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise

May 15, 2024

Erasca Announces Pricing of Underwritten Offering of Common Stock

May 15, 2024

Erasca Reports First Quarter 2024 Business Updates and Financial Results

May 7, 2024

Erasca to Present at the Bank of America Health Care Conference

May 6, 2024

Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting

April 23, 2024

Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results

March 26, 2024

Erasca Announces $45 Million Oversubscribed Private Placement Financing

March 26, 2024

Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials

February 13, 2024

Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

January 31, 2024

Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024

Decks in 2024